Please cascade within your department/centre/organization.
In this week’s issue:
- The March 2015 CIHR Transitional Operating Grant deadline to receive application packages for Faculty approval is Friday, February 20th. Full application procedures & timelines are available at https://mednet.med.ubc.ca/Research/GrantApplications/CIHR/Pages/CIHR-Operating-Grant.aspx (final reminder).
- New York Stem Cell Foundation – Innovator Awards
- Human Frontier Science Program – Innovative Life Science Research
- Lupus Foundation of America – 2015 Career Development Awards
- Alex’s Lemonade Stand Foundation – Phase I/II Infrastructure Grant
Awards and Honours:
- Chew Wei MBBS [HK] FRCOG [ENG] Memorial Prize in Cancer Research (reminder)
- Memorial Sloan Kettering Cancer Center – 2015 Paul Marks Prize for Cancer Research
- UBC Postdoctoral Association – Financial Literacy for Postdocs
- UBC Faculty of Medicine – Distinguished Medical Research Lecturers Seminar (reminder)
- Centre for Blood Research Seminar Series – Myeloproliferative Neoplasms: Mutations in Clinical Practice
Deadline: March 18, 2015
The New York Stem Cell Foundation is accepting applications for its annual Innovator Awards for early career investigators in the areas of translational stem cell research and neuroscience. Both awards provide $1.5 million over five years and are open to researchers based at accredited academic institutions anywhere in the world.
The Stem Cell Investigator Award supports research that explores the basic biology and translational potential of stem cells. The award supports scientists in the next phase of their career after postdoctoral work.
The Neuroscience Investigator Award supports innovative and excellent science with the probability for transforming the field of neuroscience research. Applicants are encouraged to submit proposals in the fundamental areas of developmental, cellular, cognitive, and behavioral neuroscience, broadly interpreted. Neuroscience proposals do not need to be related to stem cells.
To be eligible, candidates must have completed an M.D., Ph.D., and/or D.Phil.; be within five years of starting a faculty professorship (or comparable position) on June 1, 2015; have demonstrated the ability to independently supervise staff and research; have an outsanding publication record; and have demonstrated innovation in the translation of basic science to a clinical setting.
See the New York Stem Cell Foundation website for complete program guidelines and application instructions.
Registration Deadline: March 19, 2015
The Human Frontier Science Program, which supports international collaborations in basic life science research, is inviting applications for grants to support innovative approaches to understanding the complex mechanisms of living organisms.
HFSP offers two areas of funding — Program grants and Young Investigator grants. Program grants are designed for teams of independent scientists at all stages of their careers, while Young Investigator grants are for teams of scientists who are within five years of establishing an independent laboratory and within ten years of obtaining their Ph.Ds. Both provide three years of support for two- to four-member teams, with not more than one member from any one country (unless necessary for the innovative nature of the project). Applicants are expected to develop novel lines of research distinct from their ongoing research.
Awards of up to $450,000 a year will be determined by team size. All teams must be international in their composition, the principal applicant must be located in an HFSP member country. (Co-investigators may be located in any country.)
Applicants must register and obtain a 2016 reference number from the HFSP website by March 19, 2015. Letters of Intent must be received no later than March 31, 2015. Upon review, selected applicants will be invited to submit full applications.
For complete program guidelines, an FAQ, and application instructions, visit the HFSP Web site.
Deadline: March 31, 2015
The Lupus Foundation of America is dedicated to solving the mystery of lupus and providing caring support to those who suffer from its brutal impact. Through a comprehensive program of research, education, and advocacy, the foundation leads the fight to improve the quality of life for all people affected by lupus.
To that end, the foundation’s Career Development Award is designed to facilitate the professional development of rheumatology, nephrology, and dermatology fellows interested in lupus research leading to a career as an independent clinician-scientist. The foundation will award one or two grants in the amount of $70,000, renewable for a second year depending on progress (including a consideration about whether a lupus-specific abstract has been or will be submitted).
To be eligible, applicants must hold an M.D. (or equivalent) from an accredited institution; be a U.S. citizen or legal resident of the United States or Canada at the time of application; and be a first- or second-year fellow in an adult or pediatric fellowship program in rheumatology, nephrology, or dermatology accredited by either the American Council on Graduate Medical Education (in the U.S.) or Royal College of Physicians and Surgeons (in Canada).
Visit the Lupus Foundation website for complete program guidelines, information about previous recipients, and application instructions.
Deadline: April 10, 2015
Alex’s Lemonade Stand Foundation Grant Program is committed to eradicating childhood cancer through basic research, career development and helping to streamline translational clinical research.
The Infrastructure Grant is a five year award of up to $625,000 designed to support pediatric oncology Phase I and II clinical trials by funding infrastructure necessary to conduct these important studies. The aim of the grant is to help institutions build the capacity of their Phase I and II programs over a five year period. To help ensure sustainability of a successful program beyond year five, ALSF offers a year to year grant extension. Funds raised by the institution can be matched by ALSF from $25,000 up to $62,500 for an additional five years.
It is expected that applications will be submitted by seasoned translational/clinical scientists and will stimulate and catalyze early phase clinical trial research efforts at their institution. Unlike traditional granting mechanisms to individuals for their research efforts, these grants will be made to institutions that demonstrate a commitment to conducting early phase clinical trials. Applicants must document a need for clinical research support.
It is expected that proposals will come from outstanding pediatric cancer centers that have a strong track record of participation in Phase I and II clinical trials. The grants are to be used to enhance existing clinical trial infrastructure with the specific aim of increasing patient accrual to early phase trials. Thus, the overall goal of this granting mechanism is to increase accrual of Phase I and II studies that would not otherwise be possible. Applicants must prepare a table of expected trials and enrollment targets. Annual renewal of funding is dependent on progressive, yearly increase in the number of patients screened for/and placed on Phase I and II trials.
These grants will fund personnel who are critical to accomplishing the research mission of delivering new drugs to children with cancer including research nurses, clinical research assistants, data managers or nurse practitioners. Funds may be used for a maximum of $25,000 for critical equipment with appropriate documentation of the role it will play in the conduct or support of the clinical trial. Funds may be used for a maximum of $15,000 per year, to cover a physician’s salary or fringe.
For further information, please visit the ALSF website.
AWARDS AND HONOURS:
Deadline: February 24, 2015; 4:00pm PST
The Faculty of Medicine is now accepting nominations for the Dr. Chew Wei MBBS [HK] FRCOG [ENG] Memorial Prize in Cancer Research.
One $50,000 prize will be awarded annually to a Canadian who has made outstanding contributions to the treatment, amelioration, or cure for cancer. Among the criteria that will be considered is a distinguished record of translating scientific discoveries into clinical applications, forging partnerships with scientists and others to foster cancer research or to implement discoveries, and cultivating future leaders in the field. The prize is awarded with the expectation that the recipient will continue to demonstrate excellence in his/her field of work and serve as leaders to other scientists in the field, sharing his/her insights for years to come. Last year’s inaugural prize winner was Dr. Tak Wah Mak.
To download the nomination form, please visit http://med.ubc.ca/research/prizes/chew-wei-memorial-prize-in-cancer-research/.
Nomination Deadline: April 30, 2015
Honoring the legacy of Paul A. Marks, MD, President Emeritus of Memorial Sloan Kettering Cancer Center and a distinguished scientist, the Paul Marks Prize for Cancer Research recognizes outstanding young investigators who have made significant contributions to increasing the understanding of cancer or improving treatment of the disease through basic or clinical research.
The Paul Marks Prize is awarded every other year to up to three investigators. The first recipients were named in 2001. The winners will present their work at a scientific symposium at MSK and share a cash award of $150,000.
Nominations are now being accepted for the 2015 Paul Marks Prize. Nominees must be age 45 or younger on the date of the submission deadline, April 30, 2015. Prize winners will be announced in fall 2015.
- A letter from the nominator outlining the significance of the accomplishments for which the candidate is being recognized.
- A one-page scientific biography of the candidate.
- A list of up to eight of the candidate’s most significant published papers with brief explanations (100 words or less) of the importance of each one.
- The candidate’s curriculum vitae.
- Up to three supporting letters.
UBC Postdoctoral Association – Financial Literacy for Postdocs
Date & Time: February 17, 2015; 4:30-6pm
Location: Room 209 Student Union Building, 6138 Student Union Blvd, Vancouver
The UBC Postdoctoral Association is pleased to host a seminar on financial literacy. We will cover important topics on money management such as tax planning for international and Canadian postdocs, how to get your financial house in order, protecting intellectual property, wills and estates planning, etc. The overall goal is to share information on how to make the most of what we earn.
The seminar is free, and no registration necessary. Food and beverages will be served.
Please see attachedPosterfor details.
Date & Time: February 18, 2015; 2-4pm followed by reception
Location: Djavad Mowafaghian Centre for Brain Health Lecture Theatre, 2215 Wesbrook Mall, Vancouver
Each year, the Faculty of Medicine recognizes outstanding lecturers in our medical research fields. Candidates from basic sciences and clinical sciences are nominated by fellow faculty members on the basis of a distinguished research career, recognition in the medical community and effective contributions to student educational growth. Recipients are selected by the Faculty’s Research Council and are invited to present at the Distinguished Medical Research Lecturers seminar, where they are presented with awards.
This year, two Distinguished Medical Research Lecturers were selected: Dr. Lakshmi N. Yatham in clinical science and Dr. Timothy J. Kieffer in basic science.
A video link to Vancouver General Hospital, Vancouver Island, Northern and Interior Vancouver will be available.
Please register for this event at http://ow.ly/I7xrM.
Centre for Blood Research Seminar Series – Myeloproliferative Neoplasms: Mutations in Clinical Practice
Date & Time: February 18, 2015, 12-1pm
Location: LSC 3, Life Sciences Centre, 2350 Health Sciences Mall, Vancouver
Dr. Lynda Foltz
Head, Division of Hematology at St. Paul’s Hospital
Clinical Associate Professor, UBC
Over the last 10 years there have been significant advances in understanding the molecular mechanisms underlying the myeloproliferative neoplasms (MPN). The identification of the JAK2 V617F gene mutation has had a wide ranging impact clinical care, leading to changes in how we make a MPN diagnosis and determine prognosis. Ruxolitinib, a JAK1/2 inhibitor was developed as a targeted therapy for MPN and is commercially available for the treatment of myelofibrosis and polycythemia vera. Other JAK inhibitors continue in development. More recently, the CALR mutation was identified in most MPN patients who do not have the JAK2 mutation. Work is ongoing to further characterize the cellular role of CALR and the clinical impact of the mutation. Patients with myelofibrosis can carry additional mutations including EZH2, ASXL1, SRSF2 and IDH1/2 which are prognostically significant. Next generation sequencing can be used to for patient mutation profiling, however cost of testing remains a barrier to integration into routine clinical care.